Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

BACKGROUND: In our efforts to develop novel effective treatment regimens for multiple myeloma we evaluated the potential benefits of combining the immunomodulatory drug lenalidomide with daratumumab. Daratumumab is a novel human CD38 monoclonal antibody which kills CD38+ multiple myeloma cells via a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: van der Veer, Michael. S., de Weers, Michel, van Kessel, Berris, Bakker, Joost M., Wittebol, Shulamiet, Parren, Paul W.H.I., Lokhorst, Henk M., Mutis, Tuna
Format: Artigo
Idioma:Inglês
Publicat: Ferrata Storti Foundation 2011
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3031697/
https://ncbi.nlm.nih.gov/pubmed/21109694
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2010.030759
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars